In revising the list of expensive medicines for serious diseases that require electronic pre-authorization, EOPYY added 15 more drugs.

As already mentioned, the list includes 98 products, and 15 new ones:

• CUFENCE (treatment of Wilson’s disease).
• DARZALEX (for light chain amyloidosis).
• DOPTELET (for severe thrombocytopenia in adult patients with chronic liver disease).
• DUPIXENT (moderate to severe atopic dermatitis).
• EMGALITI (prevention of migraine).
• EVENITY (severe osteoporosis in postmenopausal women with a high risk of fracture).
• LUXTURNA (loss of vision due to hereditary retinal dystrophy).
• NEXOBRIDE (removal of a scab in adults with deep partial and continuous thermal burns).
• OLUMIANT (atopic dermatitis).
• REBLOSIL (transfusion-dependent anemia due to myelodysplastic syndromes).
• RINVOK (atopic dermatitis).
• TEGSEDI (polyneuropathy stage 1 or 2 in adult patients with hereditary transthyretin amyloidosis).
• VYNDAQEL (treatment of transthyretin-associated amyloidosis in adult patients with symptomatic stage 1 polyneuropathy and for the treatment of natural or hereditary transthyretin-associated amyloidosis in adult patients with cardiomyopathy (ATTR-CM)).
• ZEJULA (cancer of the ovaries, fallopian tubes, or primary peritoneal cancer).
• ZOLGENSMA (spinal muscular atrophy).

It is clarified that for all indications of approved medicines from the positive list, for which no relevant ministerial decision has been made to date on their inclusion in the positive list of reimbursable medicines, a preliminary approval procedure is required for their reimbursement.

Note that for hepatitis C medicines on the list, requests are made to the hepatitis C registry.

For the inclusion of the above medicines in the procedure, there is the consent of the Committee for the Control of Medicines Expenses.